EveryDose App for Cancer

Overseen By Jessica MacIntyre, DNP

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: University of Miami

Must be taking: Oral anti-cancer

Disqualifiers: Under 18, Dementia, Major psychiatric, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: 12 weeks

25 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a mobile app called EveryDose, designed to help cancer patients track their oral cancer medications. The researchers aim to understand how the app affects patients' experiences and whether it helps them adhere to their prescribed medication regimens. Depending on the results, the study may expand to explore other helpful methods. It suits those who have recently started taking a single oral anti-cancer drug, can read English or Spanish, and have internet access on a device like a smartphone or computer. As an unphased trial, this study allows patients to contribute to innovative solutions that could enhance medication management and improve their treatment experience.

Do I need to stop my current medications for the trial?

The trial does not specify if you need to stop taking your current medications. However, it requires that you are prescribed an oral anti-cancer drug as your first treatment, so you may need to discuss your current medications with the study team.

What prior data suggests that the EveryDose mobile application is safe for cancer patients?

Research has shown that the EveryDose mobile app helps patients track their medication schedules. Users have given it positive reviews, indicating its popularity and approval. Although specific safety data for EveryDose is not available, similar apps have been safely used by cancer patients to manage their medications. These apps can improve adherence to medication routines, which is crucial for treatment. As this study focuses on a mobile app rather than a drug, it is unlikely to cause any harmful effects. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Researchers are excited about the EveryDose mobile application for cancer patients because it offers a novel way to support medication adherence and management through digital means. Unlike traditional treatments that focus solely on medication, EveryDose provides patients with reminders and personalized support on their smartphones, potentially improving adherence to complex cancer treatment regimens. This digital approach also allows for real-time data collection and feedback, enabling healthcare providers to better monitor and support their patients remotely.

What evidence suggests that the EveryDose app is effective for improving adherence to cancer treatment?

Research shows that mobile apps can help cancer patients take their medicine as directed. A detailed review of studies found that these apps improve adherence to oral chemotherapy schedules. Studies have also found that mobile health tools effectively assist patients in following their treatment plans. In this trial, participants will use the EveryDose app, designed to connect patients with their healthcare teams and ensure correct medication use. The app aims to simplify following prescribed treatments, potentially improving patient health. ^{2 6 7 8 9}

Who Is on the Research Team?

Frank Penedo, PhD

Principal Investigator

University of Miami

Are You a Good Fit for This Trial?

This trial is for cancer patients who are currently prescribed oral chemotherapy. Participants should be willing to use the EveryDose mobile app to track their medication intake and share their experiences with the research team.

Inclusion Criteria

I am starting my first oral cancer drug as the only treatment.

Internet access on a smartphone, tablet, or computer

I can sign a consent form.

Exclusion Criteria

I can read and understand either English or Spanish.

Unable to provide written informed consent

History of dementia or major psychiatric disease that would interfere with study participation

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants use the EveryDose mobile application to track prescribed oral treatment for cancer

12 weeks

Regular app usage

Follow-up

Participants are monitored for satisfaction and adherence post-intervention

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• EveryDose Mobile Application

Trial Overview The FOCUS study is testing how effective the EveryDose mobile application is in helping cancer patients manage and adhere to their oral chemotherapy treatment schedules.

How Is the Trial Designed?

Group I: EveryDose Mobile Application Group Experimental Treatment 1 Intervention

Participants in this group will use the EveryDose mobile application for up to 12 weeks.

Who Is Running the Clinical Trial?

University of Miami

Lead Sponsor

Trials

976

Recruited

423,000+

Published Research Related to This Trial

The self-assessment smartphone app alerted 72.6% of users about concerning symptoms related to tobacco-induced diseases, with current smokers showing a higher incidence of symptoms like fatigue and cough, indicating a significant awareness of health issues.

During the study, the incidence of early-stage lung cancer (stages 1 and 2) increased to 24% among users, compared to 9% in the previous year, suggesting that the app may enhance early detection of lung cancer and encourage smoking cessation efforts.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Use of a Smartphone Self-assessment App for a Tobacco-Induced Disease (COPD, Cardiovascular Diseases, Cancer) Screening Strategy and to Encourage Smoking Cessation: Observational Study. Stavaux, E., Goupil, F., Barreau, G., et al.[2023]

Out of 776 health apps identified for supporting breast cancer treatment and aftercare, only 12 were classified as partially recommended and just 3 as recommended, indicating that most apps do not meet quality standards for patient support.

The evaluation criteria included user assessments and scientific benefits, highlighting that while some apps may offer potential benefits for breast cancer patients, the majority lack sufficient quality and effectiveness.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Mobile Applications Available in Germany Supporting Breast Cancer Patients During Treatment and Aftercare: a Systematic Review. Gomm, SIM., Ebner, FK., Lukac, S., et al.[2023]

A study evaluated 457 mobile health applications (MHAs) for prostate cancer antigen (PSA) dosage, finding that only 24 met the criteria for quality assessment, with an overall mean score below the acceptable threshold.

The quality of these apps was generally low, but well-developed MHAs could enhance PSA screening efforts and improve access to care, especially for patients in rural areas, potentially leading to earlier detection and treatment of prostate cancer.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A mobile health application for prostate cancer antigen dosage: is it time to say goodbye to classic screening methods? Di Bello, F., di Mauro, E., Fusco, GM., et al.[2023]

The eOncosalud app was used by 186 cancer outpatients receiving oral antineoplastic agents, allowing for real-time monitoring and early detection of adverse effects (AEs), with a total of 1,368 AEs recorded, including fatigue and diarrhea as the most common.

The app's algorithm provided automatic recommendations for managing AEs, with a positive predictive value of 51% for emergency room visits, demonstrating its effectiveness in optimizing healthcare resources and improving patient safety during treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A smartphone app to improve the safety of patients undergoing treatment with oral antineoplastic agents: 4 years of experience in a university hospital. Villanueva-Bueno, C., Collado-Borrell, R., Escudero-Vilaplana, V., et al.[2023]

A study involving 4475 breast cancer patients showed that using a smartphone app significantly improved adherence to multidisciplinary treatment (MDT) recommendations, with a notable reduction in noncompliance rates from 27.4% in 2013 to 8.8% in 2019.

Patients who used the app were 39% less likely to deviate from MDT recommendations compared to those who did not use the app, particularly improving compliance with adjuvant chemotherapy and radiotherapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A Smartphone-Based App to Improve Adjuvant Treatment Adherence to Multidisciplinary Decisions in Patients With Early-Stage Breast Cancer: Observational Study. Yu, J., Wu, J., Huang, O., et al.[2021]

A pilot study involving 40 women with breast cancer showed that using a symptom management mobile application alongside usual care led to better quality of life and lower severity of depression compared to those receiving only usual care.

The intervention group experienced less decline in general health and physical functioning during chemotherapy, suggesting that the mobile app may effectively support emotional and physical well-being during treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A Mobile Application for Symptom Management in Patients With Breast Cancer. Seven, M., Paşalak, Ş., Bagcivan, G., et al.[2022]

Mobile health monitoring allows patients with long-term conditions, like type 2 diabetes and cancer, to actively manage their medication dosages, leading to better patient care.

Studies showed that patients could effectively self-titrate their oral glucose-lowering medications and insulin, as well as adjust chemotherapy doses, with high compliance and safety through regular monitoring of their health status.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Mobile health for drug dose optimisation. Larsen, ME., Farmer, A., Weaver, A., et al.[2020]

A systematic review of 54 articles over the last 10 years found that mobile apps for cancer management are increasingly being researched, particularly for early detection, with a focus on melanoma.

Despite the growth in studies, many of the apps developed for cancer management tend to be removed from app stores after the research is completed, making it difficult for users to access them.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Mobile applications in oncology: A systematic review of health science databases. Ana, FA., Loreto, MS., José, LM., et al.[2020]

Mobile applications can effectively help manage chemotherapy-related side effects in early breast cancer patients, as shown in four out of six apps reviewed, leading to improved quality of life and reduced symptom burden.

While these apps show promise in enhancing symptom monitoring during treatment, further research is necessary to confirm their effectiveness and safety for patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Mobile applications for early breast cancer chemotherapy-related symptoms reporting and management: A scoping review. Suchodolska, G., Senkus, E.[2022]

The study aims to evaluate a smartphone application designed for real-time reporting of adverse events in cancer treatments, which could enhance early detection and management of side effects, ultimately improving patient safety and treatment outcomes.

The trial will involve 66 patients over six months, assessing the feasibility of the app and comparing the quality of life and therapy doses between those using the app and those receiving standard care, highlighting the importance of patient-reported symptoms in cancer treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Digitalization of adverse event management in oncology to improve treatment outcome-A prospective study protocol. Kestler, AMR., Kühlwein, SD., Kraus, JM., et al.[2021]

Citations

1. everydose.ai everydose.ai/

EveryDose: Home EveryDose's Intelligent Medication Cloud connects patients, care teams, and enterprises to maximize the value of medications. Schedule a Demo.

2. everydose.ai everydose.ai/news-and-blog/clinician-tips/meet-everydoses-medication-adherence-platform/

Meet EveryDose's Medication Adherence Platform 50% of people are still considered non-adherent to their prescriptions. Our integrated medication adherence platform can improve that.

3. pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov/31699713/

Impact of mobile applications on adherence to cancer ... In this systematic review and meta-analysis, we aim to evaluate the effectiveness of mobile applications in improving the adherence to oral chemotherapy and ...

4. clinicaltrials.gov clinicaltrials.gov/study/NCT05225090

Smartphone App for Cancer Medication Adherence Primary Objective: To determine the feasibility of using a medication reminder application (Medisafe App) to improve medication adherence in cancer patients ...

5. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC9642910/

Examining Medication Adherence Outcomes Among ... This review finds mHealth interventions are an acceptable approach that may improve adherence outcomes for patients with cancer.

6. everydose.ai everydose.ai/app/reviews/

Reviews We've spent years fine-tuning EveryDose into what it is today – a highly-rated medication management app that's loved by loyal users. Download Now.

7. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC9672512/

A smartphone app to improve the safety of patients ... This study aims to analyze the impact of the eOncosalud app on the management and follow-up of adverse effects (AE) in patients receiving oral antineoplastic ...

8. nature.com nature.com/articles/s41598-024-53373-w

Mobile app activity engagement by cancer patients and ... This study assessed app engagement, defined as adherence, timing, and attrition with two smartphone applications, one for adult cancer patients and one for ...

9. clinicaltrials.gov clinicaltrials.gov/study/NCT05225090

Smartphone App for Cancer Medication Adherence This study will help find out how much "pill burden" exists in patients with cancer, and how a smartphone app can help patients take medications as providers ...